FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after firstline bevacizumab plus oxaliplatin-based therapy: The randomized phase III EAGLE study

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1427-1433

  Iwamoto, Shigeyoshi ^a   Takahashi, T ^b   Tamagawa, H ^c   Nakamura, M ^d   Munemoto, Y ^e   Kato, T ^f   Hata, T ^g   Denda, T ^h   Morita, Y ⁱ   Inukai, M ^j   Kunieda, K ^k   Nagata, N ^l   Kurachi, K ^m   Ina, K ⁿ   Ooshiro, M ^o   Shimoyama, T ^p   Baba, H ^q   Oba, K ^r   Sakamoto, J ^s   Mishima, H ^t  

^a KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

^d Specified Medical Corporation Jisenkai Aizawa Hospital   (Japan)

^e FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^f KANSAI ROSAI HOSPITAL   (Japan)

^g OSAKA UNIVERSITY   (Japan)

^h CHIBA CANCER CENTER   (Japan)

ⁱ Graduate School of Health Sciences   (Japan)

^j KAGAWA UNIVERSITY   (Japan)

^k GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^l Kitakyushu General Hospital   (Japan)

^m HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ Nagoya Memorial Hospital   (Japan)

^o TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^p TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^q KUMAMOTO UNIVERSITY   (Japan)

^r UNIVERSITY OF TOKYO   (Japan)

^s Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

^t AICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Bevacizumab; Chemotherapy; Dose; Metastatic colorectal cancer; Randomized controlled trial; Second line therapy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EPISTAXIS; FEMALE; FIRST LINE THERAPY; GASTROINTESTINAL HEMORRHAGE; GENERAL ASPECTS OF DISEASE; HUMAN; HYPERTENSION; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SECOND LINE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TIME TO TREATMENT FAILURE; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; FOLLOW UP; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84946728807     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv197     Document Type: Article

References (19)

1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer 2013. http://globocan.iarc.fr (10 February 2014, date last accessed).
2. Katanoda K, Matsuda T, Matsuda A et al. An updated report of the trends in cancer incidence and mortality in Japan. Jpn J Clin Oncol 2013; 43: 492-507.
3. Cancer Statistics in Japan -2012. http://ganjoho.jp/data/professional/statistics/backnumber/2012/cancer_statistics_2012.pdf (10 February 2014, date last accessed).
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
5. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
6. Bennouna J, Sastre J, Dirk A et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol 2013; 14: 29-37.
7. Cohn AL, Hecht JR, Dakhil SR et al. SPIRITT (study 2006014): a randomized phase II study of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer. J Clin Oncol 2013; 31: (suppl; abstr 3616).
8. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
9. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
10. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
11. Mishima H, Oba K, Sakamoto J et al. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE trial). Jpn J Clin Oncol 2012; 42: 134-138.
12. Bennouna J, Borg C, Delord JP et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer 2012; 11: 38-44.
13. Lakatos E, Lan KK. A comparison of sample size methods for the logrank statistics. Stat Med 1992; 11: 179-191.
14. ICH Steering Committee. Statistical Principles for Clinical Trials (E9). Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline. pdf (24 January 24 2014, date last accessed).
15. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
16. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol 2012; 30: 3499-3506.
17. Tabernero J, Van Cutsem E, Lakomý R et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50: 320-331.
18. Petrelli F, Borgonovo K, Cabiddu M et al. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer 2013; 12: 145-151.
19. Hatake K, BV Appropriate Use Review Committee, Shirao K et al. Safety results from post-marketing surveillance (PMS) of bevacizumab (BV) in colorectal cancer patients ( pts) in Japan. In 2009 Gastrointestinal Cancers Symposium (abstr 485), San Francisco.